The role of histamine in dural vessel dilation
- PMID: 12426051
- DOI: 10.1016/s0006-8993(02)03485-6
The role of histamine in dural vessel dilation
Abstract
The pain of migraine is often throbbing suggesting an important role for the cranial blood vessels and their innervation by the trigeminal nerve. It is proposed that clinically effective anti-migraine compounds, such as 5-HT(1B/1D) agonists, have actions that include inhibiting calcitonin gene-related peptide (CGRP) release from trigeminal nerves. Human studies suggest that histamine can induce migraine possibly by activating nitric oxide (NO) synthase to promote endogenous NO production. The present studies investigated the effect of histamine and its antagonists on the cranial blood vessels using intravital microscopy to assess directly the diameter of dural arteries in sodium pentobarbitone anaesthetised rats. Electrical stimulation of a closed cranial window produces, by local depolarisation of nerves, dural vessel dilation that is monitored continuously on-line using video-microscopy and a video dimension analyser. Histamine infusion caused immediate and reproducible dilation of meningeal blood vessels (103.5+/-6%; n=40) that could be blocked by H(1)- (mepyramine) and H(2) (famotidine)-receptor antagonists (P<0.05), as well as a nitric oxide synthase inhibitor (N(G)-nitro-L-arginine methylester; P<0.05). Neurogenic dural vasodilation was not inhibited by H(2)-receptor antagonists, but was significantly inhibited by a H(1)-receptor antagonist at the high dose of 10 mg/kg. The present studies demonstrate that histamine is likely to activate NO synthase to promote NO production. There is also evidence that H(1)-receptors may be present on trigeminal neurones as the H(1)-receptor antagonist inhibited neurogenic vasodilation, albeit at a large dose.
Similar articles
-
The effect of anti-migraine compounds on nitric oxide-induced dilation of dural meningeal vessels.Eur J Pharmacol. 2002 Oct 4;452(2):223-8. doi: 10.1016/s0014-2999(02)02307-5. Eur J Pharmacol. 2002. PMID: 12354573
-
The anti-migraine 5-HT(1B/1D) agonist rizatriptan inhibits neurogenic dural vasodilation in anaesthetized guinea-pigs.Br J Pharmacol. 2001 Aug;133(7):1029-34. doi: 10.1038/sj.bjp.0704162. Br J Pharmacol. 2001. PMID: 11487512 Free PMC article.
-
The effect of adrenergic compounds on neurogenic dural vasodilatation.Eur J Pharmacol. 2001 Jul 13;424(1):53-8. doi: 10.1016/s0014-2999(01)01111-6. Eur J Pharmacol. 2001. PMID: 11470260
-
Neurogenic inflammation in the context of migraine.Microsc Res Tech. 2001 May 1;53(3):167-78. doi: 10.1002/jemt.1081. Microsc Res Tech. 2001. PMID: 11301492 Review.
-
Substance P receptor antagonists in the therapy of migraine.Expert Opin Investig Drugs. 2001 Apr;10(4):673-8. doi: 10.1517/13543784.10.4.673. Expert Opin Investig Drugs. 2001. PMID: 11281817 Review.
Cited by
-
Histamine and migraine revisited: mechanisms and possible drug targets.J Headache Pain. 2019 Mar 25;20(1):30. doi: 10.1186/s10194-019-0984-1. J Headache Pain. 2019. PMID: 30909864 Free PMC article. Review.
-
Fatigue, Sleep, and Autoimmune and Related Disorders.Front Immunol. 2019 Aug 6;10:1827. doi: 10.3389/fimmu.2019.01827. eCollection 2019. Front Immunol. 2019. PMID: 31447842 Free PMC article. Review.
-
Pituitary adenylate cyclase-activating polypeptide signalling as a therapeutic target in migraine.Nat Rev Neurol. 2024 Nov;20(11):660-670. doi: 10.1038/s41582-024-01011-4. Epub 2024 Sep 10. Nat Rev Neurol. 2024. PMID: 39256637 Review.
-
Chemical mediators of migraine: preclinical and clinical observations.Headache. 2011 Jun;51(6):1029-45. doi: 10.1111/j.1526-4610.2011.01929.x. Headache. 2011. PMID: 21631491 Free PMC article. Review.
-
Hypersensitivity to PACAP-38 in post-traumatic headache: a randomized clinical trial.Brain. 2024 Apr 4;147(4):1312-1320. doi: 10.1093/brain/awad367. Brain. 2024. PMID: 37864847 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials